Patient info Open main menu

Ichthammol Glycerin B.P.C – Summary of Product Characteristics (SmPC) for healthcare professionals

Last updated: · Text from the MHRA, as of · About this document

The Summary of Product Characteristics (SmPC) is written for healthcare professionals. Patients will find plain advice in the patient information leaflet: how to take, side effects, other medicines, pregnancy and breast-feeding.

Medicine strength:
100 mg/gram + 900 mg/gram
Contains active substances:

Summary of Product Characteristics (SmPC) - Ichthammol Glycerin B.P.C

1 NAME OF THE MEDICINAL PRODUCT

Ichthammol Glycerin BPC

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Ichthammol BPC 1973 10.0% w/w

For excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Topical bacteriostatic moisturiser

Viscous black liquid

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

For the treatment of chronic eczema.

4.2. Posology and Method of Administration

Adults, the elderly and children under 12 years

To be applied topically 1-3 times daily.

Route of administration

Topical.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Do not apply to broken skin. For external use only. Keep out of the reach of children. Store at a temperature not exceeding 25◦ C in well closed containers.

4.5. Interactions with other Medicaments and other forms of Interaction

No significant interactions have been reported.

4.6 Fertility, pregnancy and lactation

No significant problems have been reported either with pregnant women or with nursing mothers who are breast feeding; however, as with many other medicines, its use especially in the first 3 months of pregnancy, is recommended only when the benefits outweigh any risks.

4.7. Effects on Ability to Drive and Use Machines

None known.

4.8 Undesirable effects

Skin irritation has been reported.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

4.9. Overdose

Overdosage is unlikely to present a significant risk as it is applied topically; however, should it occur then treatment includes induction of emesis followed by supportive therapy which may include gastric lavage.

5. PHARMACOLOGICAL PROPERTIES

5.1. Pharmacodynamic Properties

Ichthammol has a slight bacteriostatic effect and acts in a similar manner to Coal Tar BP being used in the treatment of the less acute forms of eczema.

Glycerin is a humectant with emollient properties.

5.2. Pharmacokinetic Properties

Ichthammol is applied externally. There is little information available regarding its pharmacokinetics although it is probably not absorbed through intact skin.

5.3. Preclinical Safety Data

No relevant data.

6. PHARMACEUTICAL PARTICULARS

6.1. List of Excipients

Glycerol.

6.2. Incompatibilities

No significant major incompatibilities have been reported

6.3 Shelf life

5 years

6.4. Special Precautions for Storage

Store below 25oC.

6.5. Nature and Contents of Container

Dispensing pack

2 litre HDPE bottle, plastic screw cap with an aluminium foil lined EPE liner.

500 ml HDPE bottle with a wadless polypropylene screw cap.

Patient packs or OTC packs as appropriate

500 ml HDPE bottle with a wadless polypropylene screw cap.

200 ml amber glass bottle with a white Jay cap closure.

6.6 Special precautions for disposal

None stated

7. MARKETING AUTHORISATION HOLDER

Wise Pharmaceuticals Limited,

Hani Wells Business Park,

Unit 7,

Hardicker Street,

Manchester,

M19 2RB

United Kingdom

8. MARKETING AUTHORISATION NUMBER

PL 18374/0020

9. DATE OF FIRST AUTHORISATION/RENEWAL OF AUTHORISATION

17th February 2005

10 DATE OF REVISION OF THE TEXT

25/01/2016

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 18374/0020

Last revision stated in the text: 25 January 2016 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Ichthammol Glycerin B.P.C

Active substances Ichthammol, Glycerol
Strength 100 mg/gram + 900 mg/gram
Pharmaceutical form Viscous black liquid
Shelf life 5 years
Marketing authorisation PL 18374/0020 (first authorised 17 February 2005)
Marketing authorisation holder Wise Pharmaceuticals Limited

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.1.0 of 12 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.